Macquarie Group’s Traws Pharma TRAW Stock Holding History

Macquarie Group’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1	Closed	-$8K	–	2385
2017 Q4	$8K	Buy	+1	New	+$10.3K	﹤0.01%	2313

Other funds holding TRAW

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

TCP

Tyndall Capital Partners New York $452K AUM 26.52% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group's TRAW Position: Q1 2018 in Review

Macquarie Group sold out of Traws Pharma (TRAW) in Q1 2018, closing a stake of 1 share — an estimated $8K sold.

Macquarie Group first reported a position in TRAW in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 10 funds tracked by Wall St. Rank hold TRAW as of Q1 2018.

Macquarie Group reported no remaining Traws Pharma position as of Q1 2018 after selling out during the quarter.
Macquarie Group sold 1 Traws Pharma share in Q1 2018, an estimated $8K.
Macquarie Group first reported a position in Traws Pharma in Q4 2017 and held it in 1 quarter.
Macquarie Group's Traws Pharma position peaked at $8K in Q4 2017.
10 funds tracked by Wall St. Rank held Traws Pharma as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.